Last 46 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.04 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 41.64 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.11 | 0.68 | 0.58 | 0.92 | 0.70 | 1.44 | 0.00 | 2.21 | 2.53 | 2.44 | 3.26 | 12.26 | 18.03 | 12.76 | 2.69 | 2.47 | 3.30 | 7.49 | 8.58 | 14.47 | 12.88 |
| — | -52.6% | +90561.1% | -58.3% | -72.5% | -41.2% | -100.0% | -82.0% | -86.0% | -80.8% | +21.0% | +397.0% | +446.5% | +70.3% | -68.6% | -83.0% | -74.4% | -81.5% | -78.2% | -86.7% | -65.0% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -420.5% | -46.1% | -35.4% | -57.5% | -66.4% | -82.6% | -79.3% | -113.8% | -44.5% | -31.6% | -58.2% | -156.5% | -77.2% | -78.1% | -34.8% | -44.4% | -10.8% | -11.9% | -19.4% | -108.4% | -7.3% |
| — | +44.2% | +55.4% | +49.5% | -49.1% | -161.1% | -36.2% | +27.3% | +42.3% | +59.5% | -67.4% | -252.5% | -616.0% | -556.7% | -79.7% | +59.1% | -47.5% | -147.6% | +33.3% | -253.3% | +0.9% | |
| ROA | -296.7% | -41.9% | -30.8% | -46.4% | -47.4% | -58.2% | -53.4% | -80.1% | -38.4% | -25.2% | -37.4% | -62.9% | -34.4% | -49.6% | -26.5% | -34.5% | -8.4% | -9.2% | -15.4% | -87.3% | -5.8% |
| — | +28.1% | +42.4% | +42.1% | -23.2% | -130.9% | -42.9% | -27.3% | -11.8% | +49.2% | -41.1% | -82.5% | -310.0% | -438.5% | -72.5% | +60.5% | -44.4% | -150.9% | +29.4% | -450.2% | -67.6% | |
| ROIC | — | — | — | — | — | — | — | -2489.3% | -113.9% | -140.3% | -1476.7% | — | — | — | — | -1864.3% | -117.8% | -92.7% | -89.6% | -47.3% | -16.3% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -3845.3% | -620.3% | — | — | -265.9% | -251.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 0.05 | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | -63.2% | -47.6% | -48.1% | — | -32.2% | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.38 | 10.21 | 11.67 | 5.38 | 4.60 | 2.43 | 4.08 | 1.84 | 5.17 | 8.55 | 3.48 | 1.53 | 1.39 | 1.81 | 3.34 | 4.61 | 8.57 | 8.33 | 10.83 | 8.51 | 10.30 |
| — | +320.9% | +185.8% | +192.8% | -11.1% | -71.6% | +17.5% | +20.1% | +271.2% | +373.4% | +3.9% | -66.9% | -83.7% | -78.3% | -69.1% | -45.8% | -16.8% | -54.8% | -71.0% | +154.4% | +1175.1% | |
| Quick Ratio | 5.38 | 10.21 | 11.66 | 5.38 | 4.60 | 2.38 | 4.08 | 1.84 | 5.19 | 8.55 | 3.48 | 1.53 | 1.39 | 1.81 | 3.34 | 4.61 | 8.57 | 8.33 | 10.83 | 8.51 | 10.30 |
| — | +329.4% | +185.6% | +192.8% | -11.4% | -72.2% | +17.5% | +20.1% | +272.7% | +373.4% | +3.9% | -66.9% | -83.7% | -78.3% | -69.1% | -45.8% | -16.8% | -54.8% | -71.0% | +154.4% | +1175.1% | |
| Interest Coverage | -82753.59 | -10367.95 | -5390.00 | -8775.68 | — | -19084.69 | — | — | — | -53696.83 | — | — | — | — | -425228.73 | -75287.61 | -8047.42 | -4176.40 | -1092.29 | -9669.30 | -7329.83 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ENVB stock.
Enveric Biosciences, Inc.'s current P/E is -0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Enveric Biosciences, Inc.'s business trajectory between earnings reports.